Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-08-12 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Regulatory Filings Classification · 95% confidence The document is a press release issued by argenx announcing a partnership with Monica Seles to raise awareness for Myasthenia Gravis. It does not contain financial results, board changes, or regulatory filings, but rather serves as a general corporate announcement regarding a marketing/awareness initiative. As it does not fit into the specific categories like ER, 10-K, or MANG, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-08-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-12 English
6-K
Regulatory Filings
2025-07-31 English
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
Earnings Release Classification · 100% confidence The document is titled 'argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update'. It contains detailed financial tables (unaudited condensed consolidated interim statements of profit or loss) for the three and six months ended June 30, 2025, alongside management commentary on business performance, pipeline updates, and strategic goals. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of quarterly/periodical financial results and key highlights. H1 2025
2025-07-31 English
argenx SE, Halfjaarlijkse financiële verslaggeving
Interim / Quarterly Report Classification · 100% confidence The document is a '2025 Half-Year Financial Report' containing a management report, financial highlights, and unaudited condensed consolidated interim financial statements (balance sheet, profit or loss, cash flows, etc.). It covers a period shorter than a full fiscal year (six months), which fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-07-31 English
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
Report Publication Announcement Classification · 95% confidence The document is an announcement regarding an upcoming conference call to discuss financial results. It provides the date, time, and dial-in details for the event. It does not contain the actual financial results or the transcript of the call. According to the 'Menu vs Meal' rule, an announcement of a future report or event is classified as a Report Publication Announcement (RPA).
2025-07-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.